Since 2025, "Wooden Sister" Cathie Wood's Ark Invest has significantly increased its holdings in $Tempus AI (TEM.US)$ , having bought over 600,000 shares since the beginning of the year.

ARK Invest's interest in Tempus AI began on December 6 of last year. At that time, the ARK Genomic Evolution ETF (ARKG.US) first purchased shares of this medical technology company. Since then, Tempus AI's share in the ARK portfolio has rapidly increased, becoming the tenth largest holding in the flagship ARK Innovation ETF (ARKK.US); it currently accounts for 3.2% of ARKK's total assets, with a market cap of over $0.265 billion. Additionally, Tempus AI is also the fourth largest holding in the ARK Genomic Evolution ETF, accounting for 5.64%, with a market cap close to $68 million.

In January 2025, the ARK Innovation ETF expanded its position in Tempus AI, buying 439,536 shares; the ARK Genomic Evolution ETF also increased its holdings, purchasing an additional 179,255 shares during the same period.

Data shows that Tempus AI's stock price has increased by 62.4% year-to-date, with a closing price of $54.84 on Thursday. However, this is still down over 31% compared to the historical high of $79.49 set on November 12 last year. Looking at a longer timeframe, Tempus AI has risen 20.3% since its listing on January 14, 2024.

Information shows that Tempus AI is a company that uses AI to drive transformation in the medical field. In other words, the core goal of the company is to help doctors diagnose diseases more accurately through AI, especially in the field of oncology. It not only analyzes patients' genetic data and health records but also combines a vast amount of medical data resources to provide personalized and efficient treatment recommendations for doctors.

Tempus AI has established deep partnerships with over 200 biopharmaceutical companies. Meanwhile, more than half of oncologists in the USA are using its technology. The technology and data resources of Tempus AI are its core competitive advantages, and the company currently has a molecular recognition database with a scale of over 200 PB, providing a solid foundation for AI analysis and offering tremendous support for drug research and development, clinical trials, and personalized treatment.

As of now, Tempus AI has obtained 271 patents, of which 218 are valid. These patents cover core areas such as AI algorithms and genetic data analysis, far ahead of Other competitors in the Industry. Strong intellectual property not only protects Tempus AI's technological advantages but also keeps it consistently leading in competition.

According to the latest investor report, Tempus AI expects total revenue to reach 1.23 billion USD in 2025 (a year-on-year increase of over 75%), a figure that far exceeds the market's average expectation of 0.935 billion USD (a year-on-year increase of 34%). However, this growth does not solely come from the expansion of the company’s internal Business but also includes additional revenue generated through the acquisition of Other companies.

Want to know more about Cathie Wood's hold positions? Mooers canOpen futubull > Market > US Stocks > Institutional Tracking,Check out more content!

Editor/rice